Dr. Debu Tripathy discusses recent research on the use of circulating tumor DNA in metastatic breast cancer care. Circulating tumor DNA, also referred to as ctDNA, are small pieces of DNA that are ...

We conducted a systematic meta-analysis of 30 studies involving 3,287 patients with postoperative NSCLC to evaluate the diagnostic performance of ctDNA-based MRD testing for recurrence detection and ...

A study led by scientists at NYU Langone Health and its Perlmutter Cancer Center has shown that monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer ...

Low baseline ctDNA levels in advanced breast cancer patients predict better response to targeted therapy and longer ...

or on the link below. The growing sophistication of tumor molecular profiling has helped to slowly transition oncologic care toward a more personalized approach in different tumor types, including in ...

A personalized blood test known as a circulating tumor DNA (ctDNA) test—which detects tiny fragments of cancer DNA ...

Scientists have developed a blood test that can help predict which breast cancer treatment will work best. The team at the ...

Large Language Models in Population Oncology: A Contemporary Review on the Use of Large Language Models to Support Data Collection, Aggregation, and Analysis in Cancer Care and Research This work ...

Patients found to have positive lymph nodes after robotic radical cystectomy for muscle-invasive bladder cancer may benefit from treatment de-escalation if they have undetectable circulating tumor DNA ...

Data confirms Versamune® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025 Versamune® HPV + CRT ...